| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | AA | AB | AC | AD | AE | AF | AG | AH | AI | AJ | AK | AL | AM | AN | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Original Deal Snapshot | Original Deal Date | Restated Snapshot | Restated Deal Date | R&D | Client | Stage at Restatement | Type of Change(s) in Restated Deal | Key Changes Made in Restated Agreement | Deal Types | Deal Size ($M) | Maximum Share (%) | Termination Date | Exclusivity | Deal Subject | Upfront Cash ($M) | Upfront Equity ($M) | Contingent Equity ($M) | R&D Support ($M) | FTE Rate ($M) | Loan ($M) | Dev / Reg Milestones ($M) | Other Milestones ($M) | Total Precommercial Payments ($M) | Sales Milestones ($M) | Deal Size ($M) | EFR$200M (%) | EFR$500M (%) | EFR$1B (%) | Maximum Royalty (%) | Marketing Fee (%) | Transfer Price (%) | Manufacture Cost + (%) | Profit Split (%) | Disease | Indication | Technology | Sub-Technology | Territory | Financial Term Explanations |
2 | Commercial Alliances: | |||||||||||||||||||||||||||||||||||||||
3 | Link | 10/2010 | Link | 7/2012 | Amicus Therapeutics | GlaxoSmithKline | Phase III, Phase II, Preclinical | Dev Cost; Milestones; Royalty; Territory | 20% co-dev to 40% by Amicus; $93.5M dev milestones to $3.5M; $80M sales milestones to $0; 14-19% royalty to royalty-free; Worldwide to Ex-US | Co-Development, Equity, License, Restatement, Termination | 22.10 | 11/2013 | Exclusive | Amigal (migalastat) & combinations for Fabry disease ex-US | 18.60 | 0.30 | 3.50 | 22.10 | 22.10 | Endocrinological & Metabolic | Lysosomal Storage Disorders | Synthetics | Small Molecule | Africa, Asia, Europe, Middle East, NAFTA, South America | 2.95M shs @ $6.30/sh (107% of FMV) per 7/17/12 PR | GSK sales are royalty-free; Amicus has 5% royalty on Co-Formulation Product in US | |||||||||||||||
4 | 2/2009 | 6/2012 | AmpliPhi Biosciences | Celladon | Phase II | Milestones; Royalty | $20M dev milestones to $0; 10% royalty to royalty-free | License, Restatement | Exclusive | Mydicar (AAV/Serca2) for congestive heart failure | Cardiovascular | Congestive Heart Failure | Oligonucleotides | Gene Therapy | Worldwide | royalty-free | no milestone payments | ||||||||||||||||||||||||
5 | 10/2000 | 6/2011 | RespireRx Pharmaceuticals | Servier | Lead Molecule | Upfront; Milestones; Royalty; Territory | Add'l $1M upfront plus $2M in add'l milestones for expanded territory to worldwide (was ex-NA, SA & Oceania); from royalty-free to 2.25% royalty | License, Option, Research, Supply | 3.88 | 2.25 | Exclusive | Ampakine (CX1632) to treat neurodegenerative diseases ex-NA, SA & Oceania | 1.00 | 0.88 | 2.00 | 3.88 | 3.88 | 2.25 | 2.25 | 2.25 | 2.25 | Central Nervous System, Psychiatric | Alzheimer's Disease, Anxiety, Dementia | Synthetics | Small Molecule | Africa, Asia, Europe, Middle East | $2M if Servier exercised assignment option | |||||||||||||
6 | Link | 2/2007 | Link | 11/2010 | Arbor Pharmaceuticals, XenoPort | GlaxoSmithKline | Phase III, Formulation | Milestones; Royalty; Profit Split if CoPromote; Territory | $160M neuropathic pain milestones to $200M; 10% royalty (< $500M/yr) if no PS to 15-30%; 20% PS (<$750M/yr) to 20-50% PS; WW ex-Asia to US only | Co-Development, Co-Promotion, Equity, License, Restatement, Termination | 645.00 | 50.00 | 11/2012 | Exclusive | Horizant (gabapentin enacarbil) for pain & restless leg syndrome in US | 40.00 | 115.00 | 200.00 | 355.00 | 290.00 | 645.00 | 15.63 | 20.75 | 25.38 | 30.00 | 50.00 | Central Nervous System | Other Central Nervous System, Pain | Drug Delivery | Oral, Sustained Release | NAFTA | 20M eq on 11/12 termination, plus add'l $20M eq put | 15-30% US royalty in event XenoPort doesn't co-promote | $115M for RLS | 20-50% US P/L split if XenoPort co-promotes, increasing with annual sales | ||||||||
7 | 8/2003 | 9/2010 | Procom | Somaxon (now Pernix Therapeutics) | Approved | Field | Narrowed the range of Doxepin dosage deemed to be Licensed Product | License, Restatement | 5.00 | Exclusive | Doxepin, amitriptyline, trimipraline, Trazodone & nortriptyline for insomnia | 5.00 | 5.00 | 5.00 | 5.00 | Central Nervous System | Sleep Disorders | Synthetics | Small Molecule | Worldwide | ||||||||||||||||||||
8 | Link | 6/2004 | Link | 10/2009 | Vanda Pharmaceuticals | Novartis | Approved | Role Reversal in NA; Upfront; Milestones; Royalty | Was $0.5M upfront, $17.5M dev & $75M sales milestones plus 25% royalty by Vanda for WW rights; to regain NA, Novartis paid $200M upfront, $40M dev & $225M sales milestones plus 10-16% royalty | Equity, License, Restatement, Settlement, Termination | 490.00 | 16.00 | 12/2014 | Exclusive | Fanapt (iloperidone) for schizophrenia in NA | 200.00 | 25.00 | 40.00 | 265.00 | 225.00 | 490.00 | 10.00 | 11.00 | 13.00 | 16.00 | Psychiatric | Schizophrenia | Synthetics | Small Molecule | NAFTA | $25M equity purchased by Novartis in connection with 12/14 termination and settlement | |||||||||
9 | Link | 6/2007 | Link | 7/2009 | Zalicus (now Epirus Biopharmaceuticals) | Fovea Pharmaceuticals | Phase I | Field; Milestones; Royalty | Dropped royalty-free Combinations field; $20M dev milestones to $24.75M; $10M add'l milestone to $15M; $25M sales milestones added; all royalty tiers increased by 1% | Co-Development, License, Restatement | 64.75 | 12.00 | Exclusive | FOV 1801 (prednisporin) for glaucoma ex-NAFTA, S Korea & Singapore | 24.75 | 15.00 | 39.75 | 25.00 | 64.75 | 4.00 | 5.60 | 8.00 | 12.00 | Ophthalmic | Glaucoma | Synthetics | Combinatorial | Africa, Asia, Europe, Middle East, South America | $15M if approved for keratoconjunctivitis sicca | 4-12% for Licensed Products (worldwide); royalty-free for Collaboration Combinations in each party's respective territory | |||||||||||
10 | Link | 12/2005 | Link | 5/2009 | XenoPort (now Arbor Pharmaceuticals) | Astellas Pharma | Phase III | Royalties; Supply | 13-15% royalties to 15% base plus up to 3% based on NHI price; supply (@ manu cost plus 25%) transferred to Astellas | Co-Development, License, Restatement | 85.00 | 18.00 | Exclusive | Regnite (XP13512 gabapentin) for neuropathic pain in Japan, Korea, Taiwan & ASEAN | 25.00 | 40.00 | 20.00 | 85.00 | 85.00 | 15.00 | 15.00 | 15.00 | 18.00 | Central Nervous System | Pain | Synthetics | Small Molecule | Asia | 15% Basic Royalty Rate, plus up to 3% depending on NHI Price in Japan | |||||||||||
11 | 12/2004 | 2/2009 | AmpliPhi Biosciences | Celladon | Phase I | Dev Cost; Milestones; Royalty; Supply | CoDev to License only; $11.5M dev milestones to $20M; 20-25% PS to 10% royalty; full to no supply | License, Restatement, Termination | 23.70 | 10.00 | 6/2012 | Exclusive | Mydicar (AAV-based calcium release in sarcoplasmic reticulum) for congestive heart failure | 3.70 | 20.00 | 23.70 | 23.70 | 10.00 | 10.00 | 10.00 | 10.00 | Cardiovascular | Congestive Heart Failure | Oligonucleotides | Gene Therapy | Worldwide | 10%, subject to a buy-down to 5% for $50M | $3.7M for manu process dev (see Supply agmt) | |||||||||||||
12 | 3/1999 | 1/2009 | Sanofi, Genzyme | Exact Sciences | Diagnostic | Milestones; Royalty | Was $250K dev milestones & now $1.5M dev & $3M sales milestones; was 3% royalty & now 5-7.5%, depending on price | Development, License, Research | 4.65 | 7.50 | Non-exclusive | Stool-based disease detection, colorectal cancer screening | 0.15 | 1.50 | 1.65 | 3.00 | 4.65 | 7.50 | Cancer, Unlimited | Colorectal | Diagnostics, Screening | Worldwide | $150K per 7/99 original agmt | 5-7.5%, depending on volume and price | |||||||||||||||||
13 | 3/2007 | 7/2008 | Cambridge Heart | St. Jude Medical (now Abbott) | Device | Exclusivity; Marketing Fee | Was semi-exclusive for 20% agent fee; now non-exclusive marketing representative (no agent fee); no more board observer rights | Co-Market, Restatement | Non-exclusive | HearTwave implantable ECG measurement system in NAFTA | Cardiovascular | Diagnosis - Contrast/Imaging | Device | NAFTA | ||||||||||||||||||||||||||
14 | Link | 2/2004 | Link | 7/2008 | Xoma | Novartis, Chiron | Phase I | Co-Dev; Field; Milestones; Royalty | Was Co dev, $50M loan & 30% PS for 4 Mabs; now no co-dev, $14M milestones & 10-18% royalty for two Mabs | Development, License, Loan, Restatement, Supply | 27.70 | 18.00 | Exclusive | HCD122 (hu MAb to CD40) and X213 (hu MAb to Prolactin rec) for lymphoma & multiple myeloma | 13.70 | 7.00 | 7.00 | 27.70 | 27.70 | 10.00 | 11.20 | 14.10 | 18.00 | Cancer | Lymphoma, Multiple Myeloma | Monoclonals | Human Abs | Worldwide | $6.2M cash plus $7.5M reduction of outstanding balance under loan agmt | Novartis pays Xoma's FTEs for process dev on X213 (LFA102) manu process (see supply contract) | |||||||||||
15 | 2/2002 | 9/2007 | Nucryst Pharmaceuticals | Smith & Nephew | Device | Royalty; Transfer Price | Was 7.5% Distribution Royalty & Manu Cost, plus up to 12.5% add'l based on GM; now 7.5% Distribution Royalty plus 7.5% Transfer Price, or 15% royalty if S&N supplies | Asset Purchase, Co-Development, License, Supply | 52.50 | 15.00 | Exclusive | Acticoat (nanocrystaline silver antimicrobial coating) as burn dressing | 7.50 | 7.50 | 45.00 | 52.50 | 15.00 | Dermatologic | Burns, Wound Healing | Drug Delivery | Other | Worldwide | 15% royalty if Nucryst is not supplying Product | |||||||||||||||||
16 | 10/2004 | 7/2007 | Novadel Pharma | Talon Therapeutics (now Spectrum Pharmaceuticals) | Preclinical, Formulation | Milestones; Royalty | NDA approval milestones reduced from $6.5M to $5M; eliminated 50% reduction of royalty rates until recovery of Licensee's dev costs via Sublicensee Fees | Development, Equity, License, Supply | 11.50 | 25.00 | Exclusive | Zensana (ondansetron oral spray) to prevent chemo nausea & vomiting in NA | 11.50 | Cancer | Other Cancer | Drug Delivery | Oral | NAFTA | ||||||||||||||||||||||
17 | Link | 3/2002 | Link | 7/2007 | The Medicines Company | Nycomed Pharma | Filed | Milestones; Transfer Price; Upfront | Was $2.5M indication milestone & 50% Transfer Price to TMC; now TMC pays $40M at restatement, $5M indication milestone & 12.5% Transfer Price for Nycomed's distribution services | Distribution, Equity, Termination | 5.00 | 50.00 | 7/2007 | Exclusive | Angiomax (bivalirudin) as thrombin inhibitor in Europe | 5.00 | Cardiovascular | Restenosis | Europe | |||||||||||||||||||||
18 | Link | 1/2006 | Link | 6/2007 | Zalicus (now Epirus Biopharmaceuticals) | Fovea Pharmaceuticals | Discovery | Dev Cost; Territory | Was worldwide license w co-dev option for combination products; now independent dev of collab product by territory | Co-Development, License, Research, Restatement, Termination | 30.00 | 11.00 | 7/2009 | Exclusive | Cytokine modulator combinations for ophthalmic diseases ex-NAFTA, Singapore & S. Korea | 20.00 | 10.00 | 30.00 | 30.00 | 3.00 | 4.60 | 7.00 | 11.00 | Ophthalmic | Broad Focus Ophthalmic | Synthetics | Combinatorial | Africa, Asia, Europe, Middle East, South America | 3-11% for Licensed Products (worldwide); royalty-free for Collaboration Combinations in each party's respective territory | |||||||||||
19 | Link | 12/2002 | Link | 4/2007 | Eyetech (now Astellas Pharma) | Pfizer | Approved | Dev Cost; Milestones; Royalty; Territory | Each pays 100% of specific ongoing trials; WW to ex-US & dropped milestones, royalty, co-promote & profit split | Co-Development, License, Restatement, Supply | Exclusive | Macugen (VEGF inhib) for age related macular degeneration and diabetic macular edema ex-US | Ophthalmic | Age-Related Macular Degeneration, Other Ophthalmic | Oligonucleotides | Ligands | Africa, Asia, Europe, Middle East, NAFTA, South America | each pays 50% of FBMC under Degussa agmt | each pays for clinical trials in its Territory | royalty-free to both parties | ||||||||||||||||||||||
20 | 5/2006 | 4/2007 | INEX Pharmaceuticals (now Arbutus Biopharma) | Hana Biosciences (now Spectrum Pharmaceuticals) | Phase II, Preclinical, Formulation | Field | Restatement excludes MD Anderson patents from License | Equity, License | 42.00 | 10.00 | Exclusive | Marqibo (vincristine), Alocrest (vinorelbine) & Brakiva (topotecan) liposomal dev for cancer | 42.00 | Cancer | Broad Focus Cancer | Drug Delivery | Liposomes | Worldwide | ||||||||||||||||||||||
21 | Link | 8/2004 | Link | 2/2007 | Halozyme Therapeutics | Baxter | Approved, Formulation | Upfront; Equity; Milestones; Royalty; Territory | Was 50% PS for US only; now $10M upfront, $20M eq, $25M milestones & 30% TP for worldwide | Distribution, Restatement, Supply | 55.00 | 30.00 | Exclusive | Hylenex human PH20 hyaluronidase for improved drug absorption | 10.00 | 20.00 | 5.00 | 35.00 | 20.00 | 55.00 | 30.00 | Unlimited | Adjuvant, Drug Delivery, Recombinant DNA | Other | Worldwide | $10M on Restatement date | $20M for 2.07M shares in 2/07, per Halozyme's 2007 10-K | ||||||||||||||
22 | Link | 9/2003 | Link | 7/2006 | Alnylam | Merck | Discovery | Dev Cost; Field; Milestones; Royalty | Was no R&D funding, $2M milestone & 5-8% US royalty on Merck Products; now 50% US co-dev @ $485K/FTE, 9 Merck targets & 1 excluded, $5.5M co-dev, $30.5M opt-out & $41M Merck milestones, 5-10% US royalty on Merck Products (for co-dev: same 50% PS US & 10-15% ex-US) | Co-Development, Co-Promotion, License, Option, Research, Restatement, Termination | 84.50 | 50.00 | 9/2007 | Exclusive | RNAi for nine non-druggable targets | 0.49 | 41.00 | 43.50 | 84.50 | 84.50 | 10.00 | 11.40 | 13.00 | 15.00 | 50.00 | Unlimited | Oligonucleotides | RNAi | Worldwide | 10-15% ROW royalty for RNAi Products; 5-10% on Merck Development Products | $30.5M for Opt-out RNAi Product; $5.5M for Profit Sharing RNAi Product; $7.5M on Merck's Opt-in for RHOA Product | 50/50 PS on Profit Sharing RNAi Products in US | $41M for Merck Development Products | ||||||||||
23 | Link | 6/1998 | Link | 7/2006 | Aradigm | Novo Nordisk | Phase III, Formulation | Co-dev; Milestones; Royalties | Was co-dev with 11% PS; now Novo pays all dev & lower royalty only (no milestones) | Assignment, Equity, License, Loan, Restatement | 29.10 | 5.30 | Exclusive | AERx insulin Diabetes Management System for inhaled insulin | 20.00 | 1.60 | 7.50 | 29.10 | 29.10 | 5.30 | Endocrinological & Metabolic | Diabetes | Drug Delivery | Other | Worldwide | $1.6M via loan conversion in 7/10 | 3.25-5.3% royalty on First Product, depending on sales Baseline and years from launch; 4.25-5.3% royalty on any Later Product | $7.5M loan (converted to $9.1M of equity in 7/10) | ||||||||||||||
24 | Link | 6/2000 | Link | 7/2006 | King Pharmaceuticals | Wyeth (now Pfizer) | Approved | Marketing Fee; Milestones; Term | Term was until 10/08, extended until 12/10; was 15-52.5% promotion fee, with 25% residual for 2 yrs; now 30-14% promotion fee with no residual | Co-Promotion, Restatement | 170.00 | 52.50 | Exclusive | Altace (ramipril) ACE inhibitor in US | 75.00 | 75.00 | 150.00 | 20.00 | 170.00 | 52.50 | Cardiovascular | Hypertension | Synthetics | Small Molecule | NAFTA | 15-52.5% for 2006; 30% for 2007; 22.5% for 2008; 14.2% for 2009; 25% for 2010 but $5M max | $75M at signing (see separate analysis) | $75M eq at signing (see separate analysis) | ||||||||||||||
25 | Link | 1/2004 | Link | 7/2006 | Archemix | ARCA Biopharma | Preclinical | Upfront; Co-Dev; Equity; Milestones; Royalty | Was $3M upfront, $4M R&D then 50/50 co-dev, $10M milestone & 50/50 PS; now $4M upfront, $10M eq at IPO, $5M R&D funding, $35M milestones, 6-10% royalty with 25% co-dev option for 25% PS | Co-Development, Equity, License, Option, Restatement | 54.25 | 10.00 | Exclusive | ARC183 thrombin inhibitor for use in coronary artery bypass graft surgery | 4.00 | 10.00 | 5.25 | 0.37 | 35.00 | 54.25 | 54.25 | 6.50 | 7.60 | 7.80 | 10.00 | 25.00 | Cardiovascular | Atherosclerosis/Coronary Artery Disease, Other Cardiovascular | Oligonucleotides | Ligands | Worldwide | Archemix has option to co-dev by reimb 25% of all prior and on-going dev costs plus milestones; then receive 25% PS of all Product sales | $10M equity at Archemix' IPO | ||||||||
26 | 6/1999 | 4/2006 | EUSA Pharma, Jazz Pharmaceuticals, Cytogen | Progenics Pharmaceuticals | Discovery | Buyout; Milestones; Royalty; Territory | Was 50% PS for NA; now $13.2M buyout payment by Progenics, $7M dev & $45M sales milestones, and 2-5% royalty for worldwide rights | Asset Purchase, Joint Venture, License, Termination | 5.10 | 50.00 | 4/2006 | Exclusive | PSMA LLC for prostate cancer | 5.10 | Cancer | Prostate | Vaccines | Worldwide | ||||||||||||||||||||||
27 | Link | 8/2003 | Link | 2/2006 | Memory Pharmaceuticals | Roche | Preclinical | Field; Milestones; Royalty | Added 2 types of Compound; Added $53M dev & $17.5M sales milestones for new Compounds; lowered royalty tiers for new Compounds | Co-Development, Co-Promotion, License, Restatement, Termination | 211.20 | 18.00 | 12/2010 | Exclusive | MEM 3454 (nicotinic alpha-7 agonist) for neuro & psychiatric disorders | 28.00 | 105.70 | 133.70 | 77.50 | 211.20 | 9.00 | 9.00 | 10.00 | 18.00 | 20.00 | Central Nervous System, Psychiatric | Alzheimer's Disease, Broad Focus Central Nervous System, Broad Focus Psychiatric, Schizophrenia | Synthetics | Small Molecule | Worldwide | $28M for MEM3454 for Neuro | $53M for MEM3454 for other; $30M for Memory Products; $22.7M for Collaboration Products | 20% of US gross profits if pays 15% of Ph III global dev costs plus 25% of US marketing costs | |||||||||
28 | 9/2001 | 12/2005 | Lilly | InterMune (now Targanta Therapeutics) | Phase II | Upfront; Milestones; Royalty | Was $50M upfront, $95M in dev milestones plus 22-27% royalty to Lilly; now $1M upfront, $20M dev & $15M sales milestones plus 10-18% royalty to Lilly | Asset Purchase, Development, License, Research | 145.00 | 27.00 | Exclusive | Oritavancin (LLY 333328) glycopeptide as antibiotic | 10.00 | 10.00 | 20.00 | 15.00 | 145.00 | 10.00 | 12.40 | 15.20 | 18.00 | Infectious-Bacterial | Broad Focus Infectious-Bacterial | Peptides | Worldwide | |||||||||||||||
29 | Link | 10/2003 | Link | 10/2005 | PDL BioPharma | Roche | Phase II | Field; Upfront; Milestones | Was $17.5M upfront, $187M milestones, 50% PS in US & 17.5-30% royalty ROW; added chronic transplant field for add'l $10M upfront and add'l $117.5M milestones | Co-Development, Co-Promotion, License, Restatement, Supply, Termination | 367.50 | 50.00 | 8/2006 | Exclusive | 2nd Generation Zenapax (daclizumab s.c.) for asthma and chronic transplant treatment | 27.50 | 0.23 | 122.50 | 117.50 | 267.50 | 100.00 | 367.50 | 18.75 | 24.00 | 27.00 | 30.00 | 50.00 | Respiratory, Transplantation | Asthma, Organ/Tissue Transplants, Other Transplantation | Monoclonals | Humanized Abs | Worldwide | $17.5M in 9/04, plus $10M at 10/05 restatement | $65M for asthma, plus $35M for chronic transplant | equal sharing of clinical costs | Roche pays 17.5% to 30% for ex-US | $122.5M for asthma | $117.5M for chronic transplant | PDL pays Roche 50% of Gross Margin in US for Asthma; Roche pays PDL 50% of Gross Margin in US for Transplant | |||||||
30 | Link | 4/1995 | Link | 7/2005 | COR Therapeutics (now Takeda) | Schering-Plough (now Merck) | Approved | Upfront; Royalty; Territory | Was 50% PS in NA & Europe; now add'l $35.5M and 24-32% royalty | License, Restatement, Supply | 35.50 | 32.00 | Exclusive | Integrelin (Eptifibatide) for restenosis, acute MI & angina | 35.50 | 35.50 | 35.50 | 25.00 | 28.80 | 30.40 | 32.00 | Cardiovascular | Angina, Myocardial Infarction, Restenosis | Peptides | Worldwide | MPI supplies at FBMC through 3rd party vendors, subject to Put/Call (see 9/05 supply agmt) | ||||||||||||||
31 | Link | 11/2003 | Link | 7/2005 | PPD (now Furiex) | Takeda | Phase II, Preclinical | Role Reversal; Upfront; Milestones; Royalty | Was $40M equity, $17.5M milestones to Syrrx and 540% PS; now Takeda (acq. Syrrx) has worldwide rights for $15M upfront, $85.5M dev & $33M sales milestonse, plus 3-12% royalty | Development, License | 133.50 | 12.00 | Exclusive | Nesina (alogliptin DPP4 inhibitor) for type 2 diabetes | 15.00 | 85.50 | 100.50 | 33.00 | 133.50 | 7.00 | 7.00 | 8.00 | 12.00 | Endocrinological & Metabolic | Diabetes | Drug Delivery, Synthetics | Oral, Small Molecule | Worldwide | 7-12% in US; 4-8% in EU & Japan; 3-7% in ROW | |||||||||||
32 | Link | 2/2004 | Link | 5/2005 | Xoma | Chiron (now Novartis) | Discovery | Field; Royalty | Was 30% PS to Xoma for two targets; now 22.5% PS until dev cost repayment, with third target added | Co-Development, Co-Promotion, License, Loan, Option, Research, Termination | 60.00 | 30.00 | 7/2008 | Exclusive | CD40, M-CSF, MN & EphB3 Mabs for cancer | 10.00 | 0.28 | 50.00 | 60.00 | 60.00 | 30.00 | Cancer | Broad Focus Cancer | Monoclonals | Human Abs | Worldwide | Xoma funds 30% Chiron 70% | $50M loan facility (see separate contract) | 22.5-30% PS to Xoma, with lower rate paid until $15M differential utilized (or reduced via milestones accomplished) | |||||||||||||
33 | Link | 12/1997 | Link | 2/2005 | MedImmune (now AstraZeneca) | Abbott | Approved, Phase III | Co-Promotion; Field; Royalties | Numax added in 2/05; transfer price increased to 60%; MedI has co-promotion rights in Territory | Co-Development, Co-Promotion, Distribution, Restatement | 60.00 | Exclusive | Synagis (palivizumab) and Numax (MEDI-524) for RSV ex-US | 60.00 | 50.00 | Infectious-Viral | Respiratory Syncytial Virus/RSV | Monoclonals | Humanized Abs | Africa, Asia, Europe, Middle East, NAFTA, South America | 52.5% up to Threshold & 60% above Threshold; Threshold is $400M unless Numax is dropped, then $200M | |||||||||||||||||||
34 | 1/1999 | 1/2005 | Symyx (now Accelrys) | Dow Chemical | Other | Dev Cost; Royalties | Was $14.9M in R&D funding over 3 yrs, and 2.5% royalty; now $120M in R&D funding over 5 yrs, and 0.12% to 4.9% royalty (based on value-added) | License, Research, Restatement | 120.00 | 4.90 | Exclusive | Solution polymerization of olefins | 70.00 | 50.00 | 0.46 | 120.00 | 120.00 | 4.90 | Other/Miscellaneous | Industrial chemicals | Synthetics | Combinatorial | Worldwide | $7M/yr for Tools, $4M/yr for access , $3M/yr for Software, all for 5 yrs | $50M in R&D support over 5 yrs | 0.12% to 4.91% royalty, based on 25% of Added Value | ||||||||||||||||
35 | ||||||||||||||||||||||||||||||||||||||||
36 | University Licenses: | |||||||||||||||||||||||||||||||||||||||
37 | 8/2006 | 8/2011 | Johns Hopkins | Rosetta Genomics | Lead Molecule | Royalty | Decreased from $100K/yr to $10K/yr for 6th anniversary of signing onward | License | 0.13 | 4.00 | Non-exclusive | Human miRNAs and their evaluation with Dicer KOs | 0.13 | 0.13 | 4.00 | 4.00 | 4.00 | 4.00 | Unlimited | Oligonucleotides | RNAi | Worldwide | ||||||||||||||||||
38 | 6/2006 | 3/2009 | Max Planck Institute | Rosetta Genomics | Diagnostic | Stacking; Sublicensee Rev | Stacking offset now applies only if obligations exceed 15% cumulative royalty; sublicense rev share was 20%; now 25% with 12.5% anti-stacking floor | License | 0.40 | 6.00 | Semi-exclusive | Small expressed RNA molecules | 0.40 | 0.40 | Unlimited | Oligonucleotides | RNAi | Worldwide | ||||||||||||||||||||||
39 | 11/2000 | 10/2008 | UC San Francisco | NeurogesX | Preclinical | Milestones; Royalty | Was $1.15M milestones & 1% royalty; now no milestones and 0.5% royalty | Development, License | 0.50 | Exclusive | high dose capsaicin for neuropathic pain | 0.50 | Central Nervous System | Pain | Drug Delivery | Topical | Worldwide | |||||||||||||||||||||||
40 | 7/2004 | 7/2007 | Tel Aviv University | BrainStorm Cell Therapeutics | Lead Molecule, Orphan Indication | Royalty; Sublicensee Rev; Term | Was 5% royalty for latest of patents, 15 yrs from FCS or Orphan Status, plus 30% sublicense rev; now drops to 3% if no patent or Orphan Status, plus 25% sublicense rev through Phase II and 20% after Phase II completion | Equity, License, Research | 1.24 | 5.00 | Exclusive | Transformation of bone marrow and cord blood stem cells into neuron-like and glial-like cells | 0.10 | 1.14 | 1.24 | 1.24 | 5.00 | 5.00 | 5.00 | 5.00 | Central Nervous System | Parkinson's Disease | Cell Therapy - Stem Cells/Factors | Worldwide | ||||||||||||||||
41 | 6/2001 | 5/2007 | Oregon Health & Science University | Novacea (now Paratek Pharmaceuticals) | Preclinical | Field; Net Sales deductions | Was oncology and other disease therapies & now all uses, including diagnostics and prophylactics; elaborated definition of Net Sales deductions | Development, Equity, License | 12.75 | 2.50 | Exclusive | Vitamin D for treatment of tumors and other hyperproliferative disorders | 12.00 | 0.75 | 12.75 | 12.75 | 2.50 | 2.50 | 2.50 | 2.50 | Cancer | Solid Tumors | Worldwide | |||||||||||||||||
42 | 7/2002 | 5/2007 | University of Pittsburgh | Novacea (now Paratek Pharmaceuticals) | Phase I | Diligence; Assignment | Added CRE definition, permitted non-financial redactions of sublicense terms, and allowed assignment by first level sublicensee | Equity, License | 0.10 | 2.00 | Exclusive | Combination chemotherapy | 0.10 | 0.10 | 2.00 | 2.00 | 2.00 | 2.00 | Cancer | Broad Focus Cancer | Worldwide | |||||||||||||||||||
43 | 8/1998 | 2/2007 | Women and Children's Hospital | BioMarin | Lead Molecule, Orphan Indication | Diligence; Net Sales deductions; Term | Dev Diligence dropped; added elaborated defintion of Net Sales deductions; License/royalty was 10 yrs from 8/98 & now extends until 12/31/23 | License | 0.10 | 5.00 | Exclusive | rh N-acetylgalactosamine 4 Sulfatase for ERT for Lysosomal Storage Disease MPS IV | 0.10 | Other/Miscellaneous | Genetic Disorders | Recombinant DNA | Worldwide | |||||||||||||||||||||||
44 | 10/2001 | 9/2006 | UC Los Angeles | StemSource (now Cytori) | Lead Molecule | Milestones; Royalty; Sublicensee Rev | Was $225K milestones, 10% royalty on gene/cell therapy (3% other) & 25% of sublicensee rev; now no milestones, 4% royalty and 15% of sublicensee rev | Development, License | 1.08 | 10.00 | Exclusive | adipose-derived connective tissue stem cells for therapeutic application | 0.48 | 1.08 | 4.00 | 4.00 | 4.00 | 4.00 | Dermatologic, Other/Miscellaneous | Cosmetics, Wound Healing | Cell Therapy - Stem Cells/Factors | Worldwide | ||||||||||||||||||
45 | ||||||||||||||||||||||||||||||||||||||||
46 | ||||||||||||||||||||||||||||||||||||||||
47 | ||||||||||||||||||||||||||||||||||||||||
48 | ||||||||||||||||||||||||||||||||||||||||
49 | ||||||||||||||||||||||||||||||||||||||||
50 | ||||||||||||||||||||||||||||||||||||||||
51 | ||||||||||||||||||||||||||||||||||||||||
52 | ||||||||||||||||||||||||||||||||||||||||
53 | ||||||||||||||||||||||||||||||||||||||||
54 | ||||||||||||||||||||||||||||||||||||||||
55 | ||||||||||||||||||||||||||||||||||||||||
56 | ||||||||||||||||||||||||||||||||||||||||
57 | ||||||||||||||||||||||||||||||||||||||||
58 | ||||||||||||||||||||||||||||||||||||||||
59 | ||||||||||||||||||||||||||||||||||||||||
60 | ||||||||||||||||||||||||||||||||||||||||
61 | ||||||||||||||||||||||||||||||||||||||||
62 | ||||||||||||||||||||||||||||||||||||||||
63 | ||||||||||||||||||||||||||||||||||||||||
64 | ||||||||||||||||||||||||||||||||||||||||
65 | ||||||||||||||||||||||||||||||||||||||||
66 | ||||||||||||||||||||||||||||||||||||||||
67 | ||||||||||||||||||||||||||||||||||||||||
68 | ||||||||||||||||||||||||||||||||||||||||
69 | ||||||||||||||||||||||||||||||||||||||||
70 | ||||||||||||||||||||||||||||||||||||||||
71 | ||||||||||||||||||||||||||||||||||||||||
72 | ||||||||||||||||||||||||||||||||||||||||
73 | ||||||||||||||||||||||||||||||||||||||||
74 | ||||||||||||||||||||||||||||||||||||||||
75 | ||||||||||||||||||||||||||||||||||||||||
76 | ||||||||||||||||||||||||||||||||||||||||
77 | ||||||||||||||||||||||||||||||||||||||||
78 | ||||||||||||||||||||||||||||||||||||||||
79 | ||||||||||||||||||||||||||||||||||||||||
80 | ||||||||||||||||||||||||||||||||||||||||
81 | ||||||||||||||||||||||||||||||||||||||||
82 | ||||||||||||||||||||||||||||||||||||||||
83 | ||||||||||||||||||||||||||||||||||||||||
84 | ||||||||||||||||||||||||||||||||||||||||
85 | ||||||||||||||||||||||||||||||||||||||||
86 | ||||||||||||||||||||||||||||||||||||||||
87 | ||||||||||||||||||||||||||||||||||||||||
88 | ||||||||||||||||||||||||||||||||||||||||
89 | ||||||||||||||||||||||||||||||||||||||||
90 | ||||||||||||||||||||||||||||||||||||||||
91 | ||||||||||||||||||||||||||||||||||||||||
92 | ||||||||||||||||||||||||||||||||||||||||
93 | ||||||||||||||||||||||||||||||||||||||||
94 | ||||||||||||||||||||||||||||||||||||||||
95 | ||||||||||||||||||||||||||||||||||||||||
96 | ||||||||||||||||||||||||||||||||||||||||
97 | ||||||||||||||||||||||||||||||||||||||||
98 | ||||||||||||||||||||||||||||||||||||||||
99 | ||||||||||||||||||||||||||||||||||||||||
100 |